Track record · closed signal

PACS Group, Inc. (PACS) — closed signal from October 23, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on January 21, 2026.

Predicted vs. what happened

PACS price · publication thesis → realized outcomesplit-adjusted
$12.50 Published $16.25 Target $36.07 Window close $43.08 Peak
$12.00 – $13.00Entry zone — fair-value band
$12.50Published — price the day we called it
$16.25Target — the price the thesis aimed for
$43.08Peak — highest point inside the window, not a realized return
$36.07Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 25 days.

Peak price
$43.08
peak on January 13, 2026 — not a realized return
Peak gain
+244.6%
peak, from the publication price
Window close
$36.07
end-of-window price, context only
Days to target
25
Window
October 23, 2025 – January 21, 2026

The thesis — published October 23, 2025

Predicted growth
+30%
over the measurement window
Target price
$16.25
the price the thesis aimed for
Entry zone
$12.00 – $13.00
the fair-value band we waited for
Price at publication
$12.50
published October 23, 2025
Confidence
63%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

PACS is a risky, short-term rebound idea with leadership concerns. On 9-24, shares fell 29% after the CFO quit over policy violations. On 10-01, the NYSE gave more time to file and the company projected record first-half revenue. Price momentum is weak and a 10-09 valuation review raised flags. We will wait for clean filings and clear price strength before adding over the next 0-3 months.

Primary drivers

  • CFO quit; company may fix past reports (9-24)
  • NYSE gave more time; aiming for record first-half sales (10-01)
  • Valuation check suggested the stock may be priced too high (10-09)
  • Stock fell hard; need signs the business is stabilizing

How it played out

PACS: target reached in 25 days

Lyra published PACS on 2025-10-23 at $12.50 as a risky short-term rebound idea with 30% expected growth. The thesis pointed to leadership concerns after the CFO quit, extra NYSE time to file, projected record first-half sales, a valuation review that raised flags, weak price momentum, and the need for cleaner filings and clearer strength.

Inside the window, the stock reached the $16.25 target in 25 days. It later peaked at $43.08 on 2026-01-13, a 244.6% gain from the publication price. It ended the window at $36.07. The thesis played out, and the move went far beyond the target.

What happened during the window

On 2025-11-20, Barron's reported that PACS posted earnings for the first time in a year, with third-quarter revenue of $1.34 billion and adjusted earnings of 32 cents a share. The same article said PACS guided 2025 revenue to $5.25 billion to $5.35 billion.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.